Skip to main content
Premium Trial:

Request an Annual Quote

Stuart Lacock Joins SciGene as VP North American Sales, David Persing to Join Cepheid as CMO and CTO, Rudolph Potenzone Goes to CambridgeSoft from Ingenuity, Andrew McDonald Comes to Genesis Diagnostics from Genomic Solutions, and Others

Stuart Lacock has become vice president of North American sales for SciGene, the company said today. He will be responsible for expanding business in the USand Canada, primarily for SciGene's microarrays. Lacock joins the company from Continental Laboratory Products, where he was national sales manager. In the past, he worked in sales and sales management capacities for Bio-Rad Laboratories, Fisher Scientific, and CPI International.


David Persing will become executive vice president as well as chief medical and technical officer with responsibility for R&D of Cepheid, starting Aug. 29, the company said yesterday. He has been a company director since April 2004 and will remain on the company's board. Most recently, he was senior vice president and CSO of Corixa. Persing holds MD and PhD degrees from the Universityof California, San Francisco, and a BA in biochemistry from San JoseStateUniversity.


Rudolph Potenzone has joined CambridgeSoft as vice president of enterprise solutions. He most recently worked at Ingenuity, which he joined last March as senior vice president of business development and strategic planning. Potenzone was previously CEO of Lion Bioscience's USsubsidiary, Lion Bioscience Inc.


Andrew MacDonald has become head of the new microarray technologies division of Genesis Diagnostics, the Littleport, UK-based company said last week. He used to be a manager with Genomics Solutions.


Steven Enoch has become Peakdale Molecular's computational chemistry department head. Enoch joins the firm from Cyprotex Discovery, where he worked as a chemoinformatician.


David Stone has become chairman of the board of directors of Oscient Pharmaceuticals, the company said last week. He replaces David Singer, who became chairman after the 2004 merger of Genome Therapeutics and GeneSoft Pharmaceuticals that created Oscient, and will remain a board member. Stone has been a company director since 2001. He is a partner at Flagship Venture, a Cambridge, Mass.-based venture capital firm. Stone holds an MBA from Harvard Business School and a BS in microbiology from Colorado State University.


Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.